Crossing the blood-brain barrier has long limited the success of small-molecule drugs, with only a fraction reaching their targets. Lantern Pharma’s CEO describes the company’s platform, predictBBB.ai as “a paradigm shift” that could transform the development of treatments for brain cancers, Parkinson’s disease, and other neurological disorders.
